Definium Therapeutics, Inc. (DFTX)
44.81
+1.54
(+3.56%)
USD |
NASDAQ |
Aug 25, 16:00
44.74
-0.07
(-0.16%)
After-Hours: 19:59
Definium Therapeutics Total Liabilities (Quarterly) : 194.22M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 194.22M |
| March 31, 2026 | 122.44M |
| December 31, 2025 | 107.77M |
| September 30, 2025 | 106.32M |
| June 30, 2025 | 79.69M |
| March 31, 2025 | 52.52M |
| December 31, 2024 | 60.70M |
| September 30, 2024 | 57.58M |
| June 30, 2024 | 66.10M |
| March 31, 2024 | 79.47M |
| December 31, 2023 | 46.41M |
| September 30, 2023 | 45.57M |
| June 30, 2023 | 36.11M |
| March 31, 2023 | 25.18M |
| December 31, 2022 | 19.08M |
| September 30, 2022 | 27.31M |
| June 30, 2022 | 9.773M |
| March 31, 2022 | 12.43M |
| December 31, 2021 | 12.34M |
| Date | Value |
|---|---|
| September 30, 2021 | 12.54M |
| June 30, 2021 | 12.34M |
| March 31, 2021 | 13.20M |
| December 31, 2020 | 2.377M |
| September 30, 2020 | 4.043M |
| June 30, 2020 | 2.106M |
| March 31, 2020 | 2.386M |
| August 31, 2019 | 0.199M |
| May 31, 2019 | 0.1408M |
| February 28, 2019 | 0.2815M |
| November 30, 2018 | 0.0924M |
| August 31, 2018 | 0.0082M |
| May 31, 2018 | 0.0283M |
| February 28, 2018 | 0.0649M |
| November 30, 2017 | 0.0688M |
| August 31, 2017 | 0.4562M |
| May 31, 2017 | 0.1667M |
| February 28, 2017 | 0.0269M |
| November 30, 2016 | 0.0229M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 3.605M |
| CNBX Pharmaceuticals, Inc. | 2.672M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 112.90M |
| Fulcrum Therapeutics, Inc. | 13.26M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.113B |
| Shareholders Equity (Quarterly) | 918.68M |
| Debt to Equity Ratio | 0.0397 |
| Current Ratio | 6.947 |
| Net Debt Paydown Yield | -0.05% |